Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.
Richard P GaleIan PearceNicole EterFaruque GhanchiFrank G HolzSteffen Schmitz-ValckenbergKonstantinos BalaskasBen J L BurtonSusan M DownesHaralabos EleftheriadisSheena GeorgeDavid GilmourRobin HamiltonAndrew J LoteryNishal PatelPriya PrakashCynthia SantiagoSaju ThomasDeepali VarmaGavin WaltersMichael Andrew WilliamsArmin WolfRosina H ZakriFranklin IgweFilis AyanPublished in: The British journal of ophthalmology (2019)
Switching from aflibercept to ranibizumab led to a significant improvement in CSRT, with ~60% experiencing stabilised/improved BCVA. Therefore, patients with nAMD who have shown a suboptimal response to aflibercept may benefit from switching to ranibizumab.